The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effect of intranasal insulin on motor and non-motor symptoms of patients with Parkinson's disease over a 12-week period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: dr.dargahi
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Man and woman over 17 years old

• Patient with Parkinson's disease according to UK Parkinson's Disease Society Brain Bank Diagnostic Criteria

• Provide written informed consent to participate in the study.

• Understand that they may withdraw their consent at any time.

Exclusion Criteria:

• Pregnant and lactating women

• Patients with diabetes and taking anti-hyperglycemic drugs

• Patients with other neurodegenerative diseases like multiple system atrophy, Huntington's, Wilson's disease, Alzheimer's, Amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, etc.

• Patients who cannot walk for more than one minute without help

• A history of allergic reaction to insulin

• The presence of inflammation of nasal cavity that may prevents absorption of insulin